TN2009000551A1 - Nouveaux composes chimiques - Google Patents

Nouveaux composes chimiques

Info

Publication number
TN2009000551A1
TN2009000551A1 TNP2009000551A TN2009000551A TN2009000551A1 TN 2009000551 A1 TN2009000551 A1 TN 2009000551A1 TN P2009000551 A TNP2009000551 A TN P2009000551A TN 2009000551 A TN2009000551 A TN 2009000551A TN 2009000551 A1 TN2009000551 A1 TN 2009000551A1
Authority
TN
Tunisia
Prior art keywords
chemical compounds
new chemical
compounds
drug
excessive
Prior art date
Application number
TNP2009000551A
Other languages
English (en)
Inventor
Ioannis Sapountzis
Peter Ettmayer
Christian Klein
Andrea Mantoulidis
Steffen Steurer
Irene Waizenegger
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38792475&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000551(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of TN2009000551A1 publication Critical patent/TN2009000551A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des composés de formule générale (1), dans laquelle R1 à R3 et L sont définis dans la revendication 1, qui sont appropriés pour le traitement de maladies caractérisées par une prolifération cellulaire excessive ou anormale, et leur utilisation pour préparer un médicament possédant les propriétés mentionnées ci-dessus.
TNP2009000551A 2007-07-02 2009-12-31 Nouveaux composes chimiques TN2009000551A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07111566 2007-07-02
PCT/EP2008/058433 WO2009003999A2 (fr) 2007-07-02 2008-07-01 Nouveaux composés chimiques

Publications (1)

Publication Number Publication Date
TN2009000551A1 true TN2009000551A1 (fr) 2011-03-31

Family

ID=38792475

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000551A TN2009000551A1 (fr) 2007-07-02 2009-12-31 Nouveaux composes chimiques

Country Status (21)

Country Link
US (1) US8889665B2 (fr)
EP (1) EP2173734B1 (fr)
JP (1) JP5511658B2 (fr)
KR (1) KR20100039849A (fr)
CN (1) CN101796045A (fr)
AR (1) AR067397A1 (fr)
AU (1) AU2008270300A1 (fr)
BR (1) BRPI0814601A2 (fr)
CA (1) CA2692383A1 (fr)
CL (1) CL2008001943A1 (fr)
CO (1) CO6251316A2 (fr)
EA (1) EA201000105A1 (fr)
EC (1) ECSP099823A (fr)
IL (1) IL202625A0 (fr)
MA (1) MA32120B1 (fr)
MX (1) MX2009013935A (fr)
PE (1) PE20090837A1 (fr)
TN (1) TN2009000551A1 (fr)
TW (1) TW200911789A (fr)
UY (1) UY31198A1 (fr)
WO (1) WO2009003999A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2041116A1 (fr) 2006-07-07 2009-04-01 Boehringer Ingelheim International GmbH Dérivés d'hétéroaryle substitués par phényle et leur utilisation en tant qu'agents antitumoraux
CA2692379A1 (fr) * 2007-07-02 2009-01-08 Boehringer Ingelheim International Gmbh Nouveaux composes chimiques
PE20090837A1 (es) 2007-07-02 2009-07-24 Boehringer Ingelheim Int Nuevos compuestos quimicos
TW201014860A (en) 2008-09-08 2010-04-16 Boehringer Ingelheim Int New chemical compounds
CN102227421A (zh) 2008-09-29 2011-10-26 贝林格尔.英格海姆国际有限公司 抗增殖化合物
WO2010094695A1 (fr) 2009-02-17 2010-08-26 Boehringer Ingelheim International Gmbh Dérivés pyrimido-[5,4-d]-pyrimidine pour l'inhibition des tyrosine-kinases
JP2010235575A (ja) * 2009-03-09 2010-10-21 Konica Minolta Holdings Inc 含窒素縮合複素環化合物の製造方法
DE102009019962A1 (de) * 2009-05-05 2010-11-11 Merck Patent Gmbh 3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate
WO2011117382A1 (fr) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh Pyridyltriazoles
JP5871896B2 (ja) 2010-03-26 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂ−ｒａｆキナーゼインヒビター
UY33817A (es) 2010-12-21 2012-07-31 Boehringer Ingelheim Int ?nuevas oxindolpirimidinas bencílicas?.
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
US8889684B2 (en) 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
US9156837B2 (en) 2011-07-29 2015-10-13 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN103172617A (zh) * 2011-12-20 2013-06-26 天津市国际生物医药联合研究院 1,5-二取代-1,2,3-三氮唑三氟甲基类化合物的应用
CN103539784B (zh) * 2012-07-09 2016-08-17 中国科学院广州生物医药与健康研究院 杂环苯甲酰胺类化合物、药用组合物及其应用
WO2015143653A1 (fr) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions et méthodes associées
WO2015143654A1 (fr) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions et méthodes associées
WO2015143652A1 (fr) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions et méthodes associées
WO2016161572A1 (fr) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. Inhibiteurs de la kinase trka, compositions et procédés associés
CA2986083A1 (fr) 2015-06-11 2016-12-15 Basilea Pharmaceutica International AG Inhibiteurs de la pompe a efflux et utilisations therapeutiques correspondantes
KR101723881B1 (ko) * 2016-03-28 2017-04-07 이화여자대학교 산학협력단 신규한 트리아졸 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 오로라 키나제 관련 약학적 조성물
WO2020007729A1 (fr) * 2018-07-04 2020-01-09 Boehringer Ingelheim International Gmbh Dérivés de triazole benzamide en tant qu'agonistes de gpr142
CN116761801A (zh) * 2021-03-12 2023-09-15 四川科伦博泰生物医药股份有限公司 具有蛋白激酶抑制活性的杂环化合物、包含其的药物组合物及其制备方法和用途
WO2023205703A2 (fr) * 2022-04-19 2023-10-26 Watershed Medical, Inc. Formulation pour le traitement de troubles du système urinaire
CN114805334B (zh) * 2022-05-24 2023-06-09 深圳大学 一种QC和GSK-3β多靶向抑制剂及其制备方法与应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU507066B1 (en) 1977-09-06 1980-01-31 Sumitomo Chemical Company, Limited 2-Substituted-5-Hydroxy-1h-Imidazole 4-Carbozamide Derivatives
JPH03174153A (ja) 1989-09-20 1991-07-29 Fuji Photo Film Co Ltd カラー画像形成方法
EA000304B1 (ru) 1995-02-02 1999-04-29 Смитклайн Бичам Плс Производные индола как антагонисты рецептора 5-ht
WO1997003967A1 (fr) 1995-07-22 1997-02-06 Rhone-Poulenc Rorer Limited Composes aromatiques substitues et leur utilisation pharmaceutique
US6492403B1 (en) 1999-02-09 2002-12-10 3-Dimensional Pharmaceuticals, Inc. Methods of treating C1s-mediated diseases and conditions and compositions thereof
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
US6531478B2 (en) 2000-02-24 2003-03-11 Cheryl P. Kordik Amino pyrazole derivatives useful for the treatment of obesity and other disorders
JP2002069070A (ja) * 2000-04-07 2002-03-08 Takeda Chem Ind Ltd 複素環化合物、その製造法および用途
EP1364949A4 (fr) 2001-02-02 2005-11-23 Takeda Pharmaceutical Inhibiteur de jnk
ATE455104T1 (de) 2001-11-01 2010-01-15 Icagen Inc Pyrazolamide zur anwendung in der behandlung von schmerz
US20040010027A1 (en) 2001-12-17 2004-01-15 Pharmacia & Upjohn Spa Hydroxphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical comositions comprising them
JP2005162612A (ja) 2002-01-09 2005-06-23 Ajinomoto Co Inc アシルスルホンアミド誘導体
ATE329909T1 (de) 2002-11-27 2006-07-15 Boehringer Ingelheim Pharma 1,2,3-triazolamid-derivate als cytokininhibitoren
BRPI0414313A (pt) 2003-09-11 2006-11-07 Kemia Inc inibidores de citocinas
WO2005030704A1 (fr) 2003-09-24 2005-04-07 Methylgene, Inc. Inhibiteurs d'histone deacetylase
WO2005040152A1 (fr) 2003-10-20 2005-05-06 E.I. Dupont De Nemours And Company Azolecarboxamides substitues par heterocyclylphenyle et heterocyclylpyridile
JP4824576B2 (ja) 2003-12-03 2011-11-30 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド サイトカイン生成のインヒビターとしての１，２，３−トリアゾールアミド誘導体
CA2557856C (fr) 2004-03-09 2010-06-29 Boehringer Ingelheim Pharmaceuticals, Inc. 3-'4-heterocyclyl -1,2,3,-triazol-1-yl!-n-aryl-benzamides en tant qu'inhibiteurs de la production de cytokines pour le traitement de maladies inflammatoires
US7485657B2 (en) 2004-05-12 2009-02-03 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
CA2586870A1 (fr) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Composes modulateurs de la il-12
US7531560B2 (en) * 2004-11-10 2009-05-12 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
ES2465469T3 (es) * 2005-01-14 2014-06-05 Gilead Connecticut, Inc. Diaril ureas 1,3-sustituidas como moduladores de la actividad quinasa
JP2007076376A (ja) 2005-09-09 2007-03-29 Yanmar Co Ltd トラクタ
WO2007056016A2 (fr) 2005-11-02 2007-05-18 Kemia, Inc. Inhibiteurs de cytokine bisamide
WO2007075896A2 (fr) 2005-12-22 2007-07-05 Kemia, Inc. Inhibiteurs de cytokine heterocycliques
US20070155746A1 (en) 2005-12-23 2007-07-05 Kalypsys, Inc. Novel substituted pyridinyloxy and pyrimidinyloxy amides useful as inhibitors of protein kinases
US7858804B2 (en) 2006-04-18 2010-12-28 Boehringer Ingelheim International Gmbh Process for making cytokine inhibiting compounds containing 4- and 5-imidazolyl rings and the intermediates thereof
PE20120006A1 (es) 2006-05-15 2012-02-02 Boehringer Ingelheim Int Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
EP2041138B1 (fr) 2006-07-07 2014-06-25 Bristol-Myers Squibb Company Inhibiteurs de pyrrolotriazine kinase
EP2041116A1 (fr) 2006-07-07 2009-04-01 Boehringer Ingelheim International GmbH Dérivés d'hétéroaryle substitués par phényle et leur utilisation en tant qu'agents antitumoraux
WO2008008234A1 (fr) 2006-07-07 2008-01-17 Targegen, Inc. Inhibiteurs de type 2-amino-5-substituant-pyrimidines
TW200813033A (en) 2006-07-07 2008-03-16 Schering Corp 3, 4-di-substituted cyclobutene-1, 2-diones as CXC-chemokine receptor ligands
PE20080906A1 (es) 2006-08-17 2008-07-05 Kemia Inc Derivados heteroarilo como inhibidores de citocina
WO2008079909A1 (fr) 2006-12-21 2008-07-03 Plexxikon, Inc. Composés et méthodes de modulation des kinases, et indications connexes
WO2008089034A2 (fr) 2007-01-11 2008-07-24 Kemia, Inc. Inhibiteurs de cytokine
CA2679659C (fr) 2007-03-01 2016-01-19 Novartis Ag Inhibiteurs de pim kinase et procedes de leur utilisation
CA2692379A1 (fr) 2007-07-02 2009-01-08 Boehringer Ingelheim International Gmbh Nouveaux composes chimiques
PE20090837A1 (es) 2007-07-02 2009-07-24 Boehringer Ingelheim Int Nuevos compuestos quimicos
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
BRPI0916356B1 (pt) 2008-07-24 2022-08-23 Nerviano Medical Sciences S.R.L 3,4-diaril pirazois como inibidores da proteína quinase
TW201014860A (en) 2008-09-08 2010-04-16 Boehringer Ingelheim Int New chemical compounds
CN102227421A (zh) 2008-09-29 2011-10-26 贝林格尔.英格海姆国际有限公司 抗增殖化合物
WO2010094695A1 (fr) 2009-02-17 2010-08-26 Boehringer Ingelheim International Gmbh Dérivés pyrimido-[5,4-d]-pyrimidine pour l'inhibition des tyrosine-kinases
JP5871896B2 (ja) 2010-03-26 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂ−ｒａｆキナーゼインヒビター
WO2011117382A1 (fr) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh Pyridyltriazoles
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
US20130023531A1 (en) 2011-01-27 2013-01-24 Boehringer Ingelheim International Gmbh Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors
US8889684B2 (en) 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors

Also Published As

Publication number Publication date
US8889665B2 (en) 2014-11-18
WO2009003999A3 (fr) 2009-07-16
CL2008001943A1 (es) 2009-09-11
US20110183952A1 (en) 2011-07-28
CO6251316A2 (es) 2011-02-21
MA32120B1 (fr) 2011-03-01
AU2008270300A1 (en) 2009-01-08
IL202625A0 (en) 2010-06-30
MX2009013935A (es) 2010-01-28
UY31198A1 (es) 2009-01-30
EA201000105A1 (ru) 2010-06-30
TW200911789A (en) 2009-03-16
JP5511658B2 (ja) 2014-06-04
KR20100039849A (ko) 2010-04-16
CA2692383A1 (fr) 2009-01-08
EP2173734A2 (fr) 2010-04-14
WO2009003999A2 (fr) 2009-01-08
PE20090837A1 (es) 2009-07-24
EP2173734B1 (fr) 2016-03-23
CN101796045A (zh) 2010-08-04
ECSP099823A (es) 2010-01-29
AR067397A1 (es) 2009-10-07
BRPI0814601A2 (pt) 2019-09-24
JP2010531851A (ja) 2010-09-30

Similar Documents

Publication Publication Date Title
TN2009000551A1 (fr) Nouveaux composes chimiques
MA33606B1 (fr) Dérivés de pyrimidine en tant qu'inhibiteurs de protéine tyrosine kinase 2
MA30514B1 (fr) Nouveaux composes.
TN2015000547A1 (fr) Composes heteroaromatiques et leur utilisation comme ligands de dopamine d1
MA33302B1 (fr) 2, 4-diaminopyrimidines pour le traitement de maladies caracterisees par une proliferation cellulaire excessive ou anormale
MA29692B1 (fr) Derives de la xanthine en tant qu'agonistes selectifs du hm74a
MA41625A (fr) Composés de benzazépine dicarboxamide
MA33450B1 (fr) Dérivés d'oxazine et leur utilisation en tant qu'inhibiteurs de bace pour le traitement de troubles neurologiques
TNSN07070A1 (fr) Composes aminoheteroaryliques enantiomeriquement purs servant d'inhibiteurs de proteine-kinases
TN2009000324A1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoides
MA27675A1 (fr) Derives de piperazine et leur utilisation dans le traitement de maladies neurologiques et psychiatriques
MA38099B1 (fr) Des nouveaux composes triazolopyrazines substitues inhibiteurs des brd4
MA32506B1 (fr) Nouveaux composes
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
MA31260B1 (fr) 3-imidazolyl-indoles pour le traitement de maladies proliferatives
MY140187A (en) Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
MA39219B1 (fr) Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique
MA38284A1 (fr) Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one
MA32158B1 (fr) Thiazolyldihydroindazoles
MA33239B1 (fr) 3h-imidazo [4,5-c] pyridine-6-carboxamides en tant qu'anti-inflammatoires
MA33737B1 (fr) Dérivés de glycoside et utilisations de ceux-ci
TN2010000230A1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA31167B1 (fr) Inhibiteurs de l'activite de akt
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
MA29652B1 (fr) 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation